SEROCONVERSION SURVEILLANCE PROJECT

血清转化监测项目

• 批准号: 3804917
• 负责人: W FRICKE
• 金额: --
• 依托单位: CENTER BIOLOGICS EVALUATION RESEARCH HEMATOLOGY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3804917
• 关键词: HIV infections; blood transfusion; clotting factor; data collection; disease /disorder proneness /risk; drug quality /standard; epidemiology; health surveys; human immunodeficiency virus; interview; questionnaires

The Seroconversion Surveillance Project is a collaborative project of the FDA, the National Hemophilia Foundation, and the Centers for Disease Control designed to assess the risk of HIV infection from currently licensed clotting factor concentrates. Data are collected through questionnaires sent to Hemophilia Treatment Center and by telephone interviews with representatives of those centers. Information sought pertains to numbers of patients treated at the Center, testing results on patients, and products used. Any HIV seroconversions are investigated to determine if the infection can be attributed to use of a particular product. If so, the manufacturing processes used in preparation of the product and the current availability of the product are established. Thus far, no seroconversions have been identified in which currently available products are implicated.

血清转换监测项目是一个合作项目 FDA、国家血友病基金会和疾病中心 旨在评估目前艾滋病毒感染风险的控制措施 有执照的凝血因子浓缩物。数据通过以下方式收集 通过电话将问卷发送到血友病治疗中心 与这些中心的代表进行面谈。索取的资料 与在该中心接受治疗的患者数量、检测结果有关 在病人身上，以及使用的产品上。任何HIV血清转换都是 调查以确定感染是否可归因于使用 一种特定的产品。如果是这样的话， 产品的制备和当前产品的可获得性 都是成立的。到目前为止，还没有发现血清转换。 牵涉到目前可用的哪些产品。